-
Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital
•
Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi in a pre-Series B+ financing round, with the investment being solely provided by Cash Capital. Company Background and PipelineFounded in 2018, Gene Cradle has established itself as a leader in the development and manufacturing of…
-
Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a select group of institutional and accredited healthcare specialist investors for a private placement of 138,900,000 ordinary shares, equivalent to 27,780,000 American depositary shares (ADSs), at a purchase price of USD 3.60 per ADS. The agreement…
-
National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services
•
The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient Services for the People,” with the goal of promoting primary healthcare services that equally cover both urban and rural residents. The comprehensive plan consists of 10 key measures: Outpatient Resource Allocation and Specialized Services Enhancing…
-
Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment
•
Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval from the US FDA for its drug Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This approval reinforces the rationale behind Astellas’ July 2023 acquisition…
-
Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths
•
US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the suspension of enrollment in a clinical trial for the experimental bispecific antibody (BsAb) drug, REGN5678. This drug, which targets PSMA and CD28, is under Phase I assessment for treating prostate cancer, both as a monotherapy…
-
Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study
•
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a regulatory Phase III clinical study for its novel Bcl-2 inhibitor, lisaftoclax (APG-2575). The study will evaluate the efficacy of lisaftoclax in combination with a Bruton’s tyrosine kinase…
-
Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus
•
Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based in Ningbo, and Lifetech Scientific Corporation (HKG: 1302) have successfully accomplished the first compassionate use case utilizing Jenscare’s transjugular tricuspid valve replacement product, LuX-Valve Plus, in Hong Kong. Understanding Compassionate UseCompassionate use, also referred to…
-
GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023
•
The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking the 9th edition since its inception in 2015. The list serves as a reference tool rather than a recommendation guide. Contributors to this comprehensive list include Class 3A hospitals from various provinces across China, including…
